


**Figure S1** The relationship between baseline CD3<sup>+</sup>CD8<sup>+</sup> T cell levels and efficacy prediction in 33 patients treated with durvalumab. \*\*\*\*, P<0.0001.



**Figure S2** The relationship between baseline distribution of peripheral blood lymphocyte subpopulations and immunotherapy efficacy in different lung cancer pathological subtypes. (A) Baseline distribution of peripheral blood lymphocyte subpopulations and immunotherapy efficacy in squamous cell carcinoma. (B) Baseline distribution of peripheral blood lymphocyte subpopulations and immunotherapy efficacy in small cell carcinoma. (C) Baseline distribution of peripheral blood lymphocyte subpopulations and immunotherapy efficacy in adenocarcinoma. \*, P<0.05; \*\*, P<0.01. ns, no significance; NK, natural killer; Th, helper T; Tc/Ts, cytotoxic and suppressor T.